A renewed spike in Covid-19 cases across Asia has triggered a sharp rally in regional healthcare equities, notably among companies active in diagnostic kits, vaccines, and therapeutics. The uptrend in infections has accelerated demand for medical solutions, directly impacting valuations and investor sentiment toward select pharmaceutical and biotech stocks.